4t1 breast tumour cells  (ATCC)

Journal: Journal of Bone Oncology

Article Title: Doxorubicin enhances adipogenesis in an FGF2-dependent manner and induces a tumour-promoting secretory phenotype

doi: 10.1016/j.jbo.2026.100754

Figure Lengend Snippet: Tumour cell proliferation is increased by culture with or media transfer from doxorubicin-treated adipogenic differentiated MSC and is dependent in part on FGF2. A) Proliferation of PC3 cells was assessed at 24 h, 48 h and 72 h following I) treatment with conditioned media from doxorubicin-treated BMA or II) direct seeding on top of doxorubicin-treated BMA. B) Proliferation of PC3 following direct co-culture with day 12 adipogenic differentiated MSC that were treated at day 9 of adipogenic differentiation with vehicle control or 25 nM or 50 nM doxorubicin. PC3 cells were enumerated at 24 h, 48 h and 72 h following addition to adipogenic differentiated MSC. Proliferation of PC3 treated with 30% conditioned media isolated at C) day 10 or D) day 12 from differentiated MSC treated at day 9 of adipogenic differentiation with vehicle control or 25 nM doxorubicin. E) Proliferation of PC3 in response to treatment with 30% conditioned media isolated at day 10 from adipogenic differentiating MSC following treatment at day 9 with 25 nM doxorubicin and siRNA targeting FGF2 or non-targeting control siRNA. F) Conditioned media was collected at day 10 from differentiating MSC/BMA cells treated with vehicle or 25 nM doxorubicin at day 9 of the differentiation process. K562 or 4T1 tumour cells were treated with 30% adipocyte conditioned media and were imaged and counted 48 h after addition of conditioned media. Mean cell count normalized to vehicle control is presented. In all graphs, mean cell count is normalized to cell count at 0 h prior to addition of conditioned media. Graphs show the mean ± SEM, using the statistical test two-way ANOVA in Figure B) and one-way ANOVA in Figure C), D) and E), (*p < 0.05, ***p < 0.001; ****p < 0.0001), n = 3 biological replicates each with 3 technical replicates.

Article Snippet: PC3 prostate tumour cells (ATCC CRL-1435), 4T1 breast tumour cells (CRL-2539) and K562 leukemia tumour cells (CCL-243) were obtained from the American Type Culture Collection (ATCC, Manassas, VA).

Techniques: Co-Culture Assay, Control, Isolation, Cell Characterization

Journal: Frontiers in Immunology

Article Title: CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts

doi: 10.3389/fimmu.2024.1256766

Figure Lengend Snippet: Treatment with anti-CD5 MAb delays 4T1 homograft tumour growth in host mice. 4T1 tumour-harbouring mice received 25 μg/mouse of anti-CD5 MAb on day 0 at the same time of subcutaneous injection of 4T1 tumour cells (every two days and over the course of 24 days) (A) Scheme for treatment plan. (B) Tumour volume. Data are mean ± SEM (n = 7 mice), one representative experiment of two, *p < 0.05 (Student’s unpaired one-tailed t-test).

Article Snippet: 4T1 mouse breast mouse tumour cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA), and cultured in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum (FBS)(Invitrogen).

Techniques: Injection, One-tailed Test

Journal: Frontiers in Immunology

Article Title: CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts

doi: 10.3389/fimmu.2024.1256766

Figure Lengend Snippet: Fraction of CD8 + /CD69 + T and CD4 + /CD69 + T cells after treatment with anti-CD5 Mab in vivo . (A) The fraction of CD8 + /CD69 + T and MFI of CD69 on CD8 + T cell isolated from spleens, draining lymph nodes, and TILs isolated from 4T1 tumour-bearing BALB/c mice treated with anti-CD5 MAb or isotype Mab control. (B) The fraction of CD4 + /CD69 + T and MFI of CD69 on CD4 + T cell isolated from spleens, draining lymph node, and TILs isolated from 4T1 tumour-bearing BALB/c mice treated with anti-CD5 MAb or control isotype MAb. Data are mean ± SD ( n = 3 mice), one representative experiment of three. * p < 0.05 (Student’s unpaired one-tailed t -test). MFI, mean fluorescence intensity. ns, non significant.

Article Snippet: 4T1 mouse breast mouse tumour cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA), and cultured in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum (FBS)(Invitrogen).

Techniques: In Vivo, Isolation, Control, One-tailed Test, Fluorescence

Journal: Frontiers in Immunology

Article Title: CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts

doi: 10.3389/fimmu.2024.1256766

Figure Lengend Snippet: Level of Fas receptor on CD8 + T cells and CD4 + T cells after treatment with anti-CD5 MAb in vivo . (A) The MFI of Fas receptor on CD8 + T cells isolated from spleens, draining lymph node, and TILs isolated from 4T1 tumour-bearing BALB/c mice that were treated with anti-CD5 MAb or isotype MAb control. (B) The MFI of Fas receptor on CD4 + T cells isolated from spleens, draining lymph nodes, and TILs isolated from 4T1 tumour-bearing BALB/c mice treated with anti-CD5 MAb or control isotype MAb. Data are mean ± SD ( n = 3 mice), one representative experiment of three. * p < 0.05 (Student’s unpaired one-tailed t -test). MFI, mean fluorescence intensity. FMO, Fluorescence Minus One. ns, non significant.

Article Snippet: 4T1 mouse breast mouse tumour cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA), and cultured in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum (FBS)(Invitrogen).

Techniques: In Vivo, Isolation, Control, One-tailed Test, Fluorescence

Journal: Frontiers in Immunology

Article Title: CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts

doi: 10.3389/fimmu.2024.1256766

Figure Lengend Snippet: (A) The fraction of CD8 + /CD107a + T cells and MFI of CD107a on CD8 + T cells isolated from spleens, draining lymph nodes, and TILs from 4T1 tumour-bearing BALB/c mice treated with anti-CD5 MAb or control isotype MAb. (B) The fraction of CD4 + /CD107a + T and MFI of CD107a on CD4 + T cell isolated from spleens, draining lymph nodes, and TILs isolated from 4T1 tumour-bearing BALB/c mice that were treated with anti-CD5 MAb or control isotype MAb. Data are mean ± SD ( n = 3 mice), one representative experiment of three. * p < 0.05 (Student’s unpaired one-tailed t -test). MFI, mean fluorescence intensity. ns, non significant.

Article Snippet: 4T1 mouse breast mouse tumour cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA), and cultured in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum (FBS)(Invitrogen).

Techniques: Isolation, Control, One-tailed Test, Fluorescence

Journal: Frontiers in Immunology

Article Title: CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts

doi: 10.3389/fimmu.2024.1256766

Figure Lengend Snippet: (A) The fraction of CD8 + /CD137 + T and MFI of CD137 on CD8 + T cells isolated from spleens, draining lymph nodes, and TILs isolated from 4T1 tumour-bearing BALB/c mice that were treated with anti-CD5 MAb or control isotype MAb. (B) The fraction of CD4 + /CD137 + T and MFI of CD137 on CD4 + T cells isolated from spleens, draining lymph nodes, and TILs isolated from 4T1 tumour-bearing BALB/c mice treated with anti-CD5 MAb or control isotype MAb. Data are mean ± SD ( n = 3 mice), one representative experiment of three. * p < 0.05 (Student’s unpaired one-tailed t -test). MFI, mean fluorescence intensity. ns, non significant.

Article Snippet: 4T1 mouse breast mouse tumour cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA), and cultured in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum (FBS)(Invitrogen).

Techniques: Isolation, Control, One-tailed Test, Fluorescence